Monoclonal gammopathy of undetermined significance: A primary care guide

Jack Khouri; Christy Samaras; Jason Valent; Alex Mejia Garcia; Beth Faiman; Saveta Mathur; Kimberly Hamilton; Megan Nakashima; Matt Kalaycio

doi:10.3949/ccjm.86a.17133

Monoclonal gammopathy of undetermined significance: A primary care guide

Cleve Clin J Med. 2019 Jan;86(1):39-46. doi: 10.3949/ccjm.86a.17133.

Authors

Jack Khouri¹, Christy Samaras^{2

3}, Jason Valent^{2

3}, Alex Mejia Garcia², Beth Faiman⁴, Saveta Mathur², Kimberly Hamilton², Megan Nakashima^{5

6}, Matt Kalaycio^{7

8

9}

Affiliations

¹ Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. khourij@ccf.org.
² Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
³ Clinical Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
⁴ Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
⁵ Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH, USA.
⁶ Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
⁷ Chairman, Department of Hematology and Medical Oncology, Bone Marrow Transplant Program, Cleveland Clinic, Cleveland, OH, USA.
⁸ Transplantation Center, and Department of Cancer Biology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
⁹ Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.

PMID: 30624183
DOI: 10.3949/ccjm.86a.17133

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) is commonly diagnosed in outpatients being worked up for an array of clinical concerns. It carries a risk of progression to myeloma and other lymphoproliferative disorders that, albeit low (1% per year), warrants regular follow-up. Patients with MGUS can be risk-stratified on the basis of the amount and type of their monoclonal protein as well as whether they have an abnormal light-chain ratio. Here, we provide a guide to the diagnosis, workup, and management of MGUS.

Publication types

Review

MeSH terms

Humans
Paraproteinemias / diagnosis
Paraproteinemias / therapy*